$INO 💎🙌🏻⚽️🎾🏀 Hey FDA are you 👀this? Dr. J. Joseph Kim, President and CEO of INOVIO, said, &quot;We have observed that INO-4500 vaccination generates robust antibody and T cell immune responses in a Phase 1 clinical trial conducted in the U.S., and this continued advancement of INO-4500 into Phase 1B trial is another important step in a  fight against Lassa fever. This trial also represents a significant advancement within INOVIO&#39;s infectious disease portfolio and 👀👀further validates the company&#39;s DNA medicines platform and proprietary ® delivery device.&quot;👀👀👀

Dr. Kim added, &quot;This is the same device being used to deliver our DNA vaccine candidate, INO-4800, in the Phase 2 segment of our INNOVATE Phase 2/3 COVID-19 trial. We are grateful to CEPI for the continued support and confidence in our vaccine programs – and we look forward to advancing INO-4500 as a vaccine candidate against Lassa fever.&quot;
<ticker> 💎 🙌🏻 ⚽ 🎾 🏀 hey fda are you 👀 this ? dr . j . joseph kim , president and ceo of <company> said , we have observed that ino - <number> vaccination generates robust antibody and t cell immune responses in a phase <number> clinical trial conducted in the u . s . , and this continued advancement of ino - <number> into phase <number> b trial is another important step in a fight against lassa fever . this trial also represents a significant advancement within inovio infectious disease portfolio and 👀 👀 further validates the company dna medicines platform and proprietary ® delivery device . 👀 👀 dr . kim added , this is the same device being used to deliver our dna vaccine candidate , ino - <number> , in the phase <number> segment of our innovate phase <number> / <number> covid - <number> trial . we are grateful to cepi for the continued support and confidence in our vaccine programs and we look forward to advancing ino - <number> as a vaccine candidate against lassa fever .